sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
|
TRICOR
|
immunosuppressants
|
ADVISE
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s6
|
DDI-DrugBank.d283.s6.p0
|
Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
carbamazepine
|
Felbatol
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s31
|
DDI-DrugBank.d434.s31.p12
|
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
|
cyclosporin A
|
etoposide
|
MECHANISM
|
Etoposide_ddi.xml
|
DDI-DrugBank.d194.s1
|
DDI-DrugBank.d194.s1.p0
|
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
|
Barbiturates
|
contraceptives
|
EFFECT
|
Hexobarbital_ddi.xml
|
DDI-DrugBank.d457.s0
|
DDI-DrugBank.d457.s0.p0
|
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
|
alcohol
|
3-hydroxy-1,4-benzodiazepine
|
MECHANISM
|
9120829.xml
|
DDI-MedLine.d113.s5
|
DDI-MedLine.d113.s5.p0
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
antineoplastic agents
|
clofibrate
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p4
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
fluoxetine
|
paroxetine
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p14
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
influenza virus vaccine
|
trimethoprim
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1047
|
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
|
Mefloquine
|
tricyclic antidepressants
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s9
|
DDI-DrugBank.d220.s9.p5
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
acyclovir
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p16
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
Quinidine
|
itraconazole
|
NONE
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p4
|
Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
|
warfarin-type anticoagulant
|
griseofulvin
|
ADVISE
|
Griseofulvin_ddi.xml
|
DDI-DrugBank.d83.s0
|
DDI-DrugBank.d83.s0.p0
|
In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
|
aspirin
|
nizatidine
|
MECHANISM
|
Nizatidine_ddi.xml
|
DDI-DrugBank.d475.s3
|
DDI-DrugBank.d475.s3.p1
|
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
|
disulfiram
|
nitrite
|
EFFECT
|
Disulfiram_ddi.xml
|
DDI-DrugBank.d19.s9
|
DDI-DrugBank.d19.s9.p0
|
- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
|
Indomethacin
|
bumetanide
|
EFFECT
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s7
|
DDI-DrugBank.d331.s7.p4
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
ethionamide
|
lovastatin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p376
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
loratadine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p14
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
procainamide
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p12
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
retinyl acetate
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p8
|
Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
|
aluminum/magnesium hydroxide antacids
|
famotidine
|
NONE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s90
|
DDI-DrugBank.d531.s90.p23
|
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
|
Valdecoxib
|
warfarin
|
EFFECT
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s24
|
DDI-DrugBank.d328.s24.p2
|
Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
|
TORADOL
|
phenytoin
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s18
|
DDI-DrugBank.d3.s18.p5
|
Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
|
probenecid
|
penciclovir
|
MECHANISM
|
Famciclovir_ddi.xml
|
DDI-DrugBank.d112.s0
|
DDI-DrugBank.d112.s0.p0
|
Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
|
Enoxacin
|
digoxin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s7
|
DDI-DrugBank.d395.s7.p2
|
Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
|
Chlorpropamide
|
allopurinol
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s20
|
DDI-DrugBank.d413.s20.p4
|
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
|
atorvastatin
|
contraceptive
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s10
|
DDI-DrugBank.d140.s10.p4
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
antacids
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p2
|
Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
|
Nicotine
|
ergot
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s4
|
DDI-DrugBank.d410.s4.p2
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
triazolam
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p135
|
The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.
|
warfarin
|
cerivastatin sodium
|
NONE
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s10
|
DDI-DrugBank.d141.s10.p0
|
Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
|
ammonium chloride
|
amphetamine
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s0
|
DDI-DrugBank.d158.s0.p1
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
isoniazid
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p64
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
opioids
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p4
|
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
|
18-MC
|
morphine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s6
|
DDI-MedLine.d110.s6.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Tegretol
|
Nizoral
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p365
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
angiotensin-converting enzyme inhibitors
|
zidovudine
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p64
|
- Lofexidine may enhance the effects of anti-hypertensive drug therapy
|
Lofexidine
|
anti-hypertensive drug
|
EFFECT
|
Lofexidine_ddi.xml
|
DDI-DrugBank.d454.s2
|
DDI-DrugBank.d454.s2.p0
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
tricyclic antidepressants
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p9
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
antacids
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p3
|
Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
|
quinolone class antimicrobial
|
nonsteroidal anti-inflammatory drug
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s10
|
DDI-DrugBank.d562.s10.p0
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine
|
benzodiazepines
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p30
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
phenobarbital
|
corticosteroids
|
MECHANISM
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p2
|
However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
|
PRECEDEX
|
anesthetic
|
ADVISE
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s4
|
DDI-DrugBank.d197.s4.p5
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
norepinephrine
|
phenothiazines
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p11
|
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
|
alosetron
|
clarithromycin
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s10
|
DDI-DrugBank.d364.s10.p0
|
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.
|
secobarbital
|
glutethimide
|
NONE
|
1109248.xml
|
DDI-MedLine.d106.s1
|
DDI-MedLine.d106.s1.p11
|
In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
|
indomethacin
|
diflunisal
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s21
|
DDI-DrugBank.d132.s21.p0
|
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
|
lomefloxacin
|
terfenadine
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s23
|
DDI-DrugBank.d516.s23.p9
|
Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
|
Heparin
|
ketorolac tromethamine
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s1
|
DDI-DrugBank.d3.s1.p16
|
If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
|
ZYVOX
|
serotonergic agents
|
ADVISE
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s8
|
DDI-DrugBank.d441.s8.p0
|
Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
|
benzodiazepines
|
barbiturates
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s0
|
DDI-DrugBank.d18.s0.p1
|
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
|
ketamine
|
ouabain
|
EFFECT
|
1167743.xml
|
DDI-MedLine.d23.s1
|
DDI-MedLine.d23.s1.p10
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
choline salicylate
|
Arthropan
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p63
|
In Europe, Nimotop was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
|
Nimotop
|
antihypertensive compounds
|
EFFECT
|
Nimodipine_ddi.xml
|
DDI-DrugBank.d310.s1
|
DDI-DrugBank.d310.s1.p0
|
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
|
norethindrone acetate
|
ethinyl estradiol
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s33
|
DDI-DrugBank.d438.s33.p12
|
When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
|
agents with b-blocking properties
|
clonidine
|
ADVISE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s5
|
DDI-DrugBank.d269.s5.p0
|
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
|
antihistamines
|
tranquilizers
|
EFFECT
|
Clemastine_ddi.xml
|
DDI-DrugBank.d309.s0
|
DDI-DrugBank.d309.s0.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cimetidine
|
phenylbutazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p564
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
chlordiazepoxide
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p2
|
Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
|
L-phenylalanine
|
selective MAO inhibitor
|
NONE
|
L-Phenylalanine_ddi.xml
|
DDI-DrugBank.d530.s2
|
DDI-DrugBank.d530.s2.p3
|
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
|
valdecoxib
|
glyburide
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s33
|
DDI-DrugBank.d328.s33.p0
|
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
|
fibrate
|
lovastatin
|
EFFECT
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s6
|
DDI-DrugBank.d12.s6.p0
|
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
|
Nonsteroidal anti-inflammatory agents
|
corticosteroids
|
NONE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s24
|
DDI-DrugBank.d314.s24.p3
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
propafenone
|
quinidine
|
NONE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p32
|
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
|
Macrolide antibiotics
|
simvastatin
|
MECHANISM
|
11197581.xml
|
DDI-MedLine.d25.s12
|
DDI-MedLine.d25.s12.p4
|
Effects of Other Antiepileptic Drugs on Felbatol Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
Antiepileptic Drugs
|
felbamate
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s30
|
DDI-DrugBank.d434.s30.p4
|
In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
|
nitrates
|
vardenafil
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s22
|
DDI-DrugBank.d198.s22.p3
|
The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
|
tolbutamide
|
Atromid-S
|
EFFECT
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s5
|
DDI-DrugBank.d12.s5.p0
|
There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.
|
nifedipine
|
diltiazem
|
NONE
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s20
|
DDI-DrugBank.d87.s20.p2
|
EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
|
EDECRIN
|
cephalosporin antibiotics
|
EFFECT
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s2
|
DDI-DrugBank.d414.s2.p1
|
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1 g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5 g/kg/min. over 18 hours).
|
aspirin
|
acetaminophen
|
NONE
|
Argatroban_ddi.xml
|
DDI-DrugBank.d148.s2
|
DDI-DrugBank.d148.s2.p16
|
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
iron
|
sucralfate
|
NONE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s11
|
DDI-DrugBank.d217.s11.p8
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
nonsteroidal anti-inflammatory agents
|
probenecid
|
NONE
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p13
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
fluoxetine
|
5-HT1 agonists
|
EFFECT
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p21
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
haloperidol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p14
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Trileptal
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p9
|
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
|
butyrophenones
|
epinephrine
|
EFFECT
|
Lidocaine_ddi.xml
|
DDI-DrugBank.d564.s1
|
DDI-DrugBank.d564.s1.p2
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
somatropin
|
progestogens
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p97
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
Type 1C antiarrhythmics
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p3
|
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
|
beta-adrenergic blocking agents
|
digitalis
|
EFFECT
|
Levobunolol_ddi.xml
|
DDI-DrugBank.d252.s4
|
DDI-DrugBank.d252.s4.p0
|
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
|
erythromycin
|
fentanyl
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s3
|
DDI-DrugBank.d170.s3.p3
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
buprenorphine
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p34
|
The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
|
eszopiclone
|
ketoconazole
|
MECHANISM
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s7
|
DDI-DrugBank.d216.s7.p0
|
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
|
cephalosporins
|
aminoglycoside antibiotics
|
EFFECT
|
Ceftazidime_ddi.xml
|
DDI-DrugBank.d122.s0
|
DDI-DrugBank.d122.s0.p0
|
Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
|
tiagabine
|
phenytoin
|
MECHANISM
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s11
|
DDI-DrugBank.d277.s11.p3
|
Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
|
drugs
|
amiodarone
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s45
|
DDI-DrugBank.d143.s45.p0
|
A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
|
diltiazem
|
cyclosporine
|
INT
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s25
|
DDI-DrugBank.d565.s25.p0
|
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
|
desmethyldiltiazem
|
sirolimus
|
NONE
|
11180036.xml
|
DDI-MedLine.d86.s7
|
DDI-MedLine.d86.s7.p7
|
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
|
indinavir
|
SUSTIVA
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s38
|
DDI-DrugBank.d531.s38.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
methadone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p24
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
sildenafil
|
zidovudine
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p109
|
During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
|
TAMBOCOR
|
digoxin
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s2
|
DDI-DrugBank.d87.s2.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
methyldopa
|
methylphenidate
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1107
|
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
|
isocarboxazid
|
L-tryptophan
|
NONE
|
L-Tryptophan_ddi.xml
|
DDI-DrugBank.d63.s0
|
DDI-DrugBank.d63.s0.p20
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
phenytoin
|
diazepam
|
NONE
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p22
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Dilantin
|
morphine
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p311
|
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
|
Azithromycin
|
zidovudine
|
MECHANISM
|
11210404.xml
|
DDI-MedLine.d105.s7
|
DDI-MedLine.d105.s7.p1
|
In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
|
allopurinol
|
mercaptopurine
|
ADVISE
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s4
|
DDI-DrugBank.d413.s4.p18
|
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
|
enalapril
|
digoxin
|
NONE
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s10
|
DDI-DrugBank.d107.s10.p14
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
bismuth subsalicylate
|
Pepto-Bismol
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p77
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.